SCHEMBL6358772

SCHEMBL6358772

O=C(CCN1CCN(c2ccccn2)CC1)c1ccc(F)cc1

nearest known ligand 0.87

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DRD4 P21917 12/20 0.87
HTR1A P08908 8/20 0.87
DRD2 P14416 8/20 0.87
HTR2A P28223 5/20 0.87
DRD3 P35462 5/20 0.87
HTR2C P28335 4/20 0.87
HTR7 P34969 4/20 0.87
TMEM97 Q5BJF2 4/20 0.87
SIGMAR1 Q99720 4/20 0.87
LMNA P02545 1/20 0.87
CYP1A2 P05177 1/20 0.87
CYP3A4 P08684 1/20 0.87
CYP2D6 P10635 1/20 0.87
CYP2C9 P11712 1/20 0.87
CYP2C19 P33261 1/20 0.87
SMN1; SMN2 Q16637 1/20 0.87
ADRA2C P18825 2/20 0.65
HRH1 P35367 2/20 0.65
POLB P06746 1/20 0.61
DRD1 P21728 1/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Azaperone SCHEMBL121134 0.93 DRD4 (1.00) DRD4HTR1ADRD2HTR2ADRD3
Azaperone SCHEMBL29437229 0.93 DRD4 (1.00) DRD4HTR1ADRD2HTR2ADRD3
SCHEMBL6351416 0.90 HTR1A (1.00) DRD4HTR1ADRD2HTR2ADRD3
SCHEMBL6353714 0.89 HTR1A (0.76) DRD4HTR1ADRD2HTR2ADRD3
SCHEMBL6351426 0.88 HTR1A (0.81) DRD4HTR1ADRD2HTR2ADRD3
SCHEMBL6349767 0.88 HTR1A (0.81) DRD4HTR1ADRD2HTR2ADRD3
SCHEMBL6353873 0.88 DRD4 (0.74) DRD4HTR1ADRD2HTR2ADRD3
SCHEMBL6359034 0.87 HTR1A (0.76) DRD4HTR1ADRD2HTR2ADRD3
Azaperone SCHEMBL3087530 0.86 DRD4 (0.86) DRD4HTR1ADRD2HTR2ADRD3
SCHEMBL6359359 0.84 DRD4 (0.69) DRD4HTR1ADRD2HTR2ADRD3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050176727-A1 Oximes and hydrazones that are useful in treating sexual dysfunction ABBOTT LABORATORIES 2005-08-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050176727-A1 Oximes and hydrazones that are useful in treating sexual dysfunction CYP19A1, SHBG, CYP17A1 DRD4 1272/4885HTR1A 871/4885DRD2 1704/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.